Table 1.
Clinical characteristics of Japanese subjects with functional dyspepsia
| rabeprazole (n = 69) | itopride (n = 65) | |
|---|---|---|
| Age | 51.2 ± 15.2 (24–79) | 53.6 ± 14.2 (19–79) |
| Gender (male/female) | 27/42 | 18/47 |
| Height (cm) | 160.3 ± 7.8 | 157.9 ± 9.0 |
| Weight (kg) | 53.0 ± 11.4 | 52.6 ± 11.7 |
| Body mass index (kg/m2) | 20.5 ± 3.6 | 21.0 ± 3.8 |
| Helicobacter pylori status (positive/negative/unknown) | 23/35/11 | 29/26/10 |
| Duration of symptoms (years) | 4.5 ± 8.9 (0.5–55.0) | 4.5 ± 10.0 (0.5–55.0) |
| Medication before entry (YES/NO) | 32/37 | 36/38 |
| Type of Medicine | ||
| Proton pump inhibitor | 0 | 4 |
| Histamine 2 receptor antagonist | 12 | 16 |
| Prokinetic agent | 3 | 3 |
| Other (gastro-protective, etc.) | 17 | 28 |
| FD subgroup (EPS/PDS/overlap) | 26/35/4 | 33/33/3 |
| GSRS total score | 2.6 ± 1.0 | 2.6 ± 1.0 |
| Subscale scores | ||
| Reflux | 2.5 ± 1.1 | 2.7 ± 1.5 |
| Abdominal pain | 3.1 ± 1.4 | 2.7 ± 1.3 |
| Indigestion | 2.8 ± 1.2 | 2.6 ± 1.2 |
| Diarrhoea | 2.3 ± 1.3 | 2.3 ± 1.4 |
| Constipation | 2.5 ± 1.5 | 2.7 ± 1.2 |
| FD score | 3.0 ± 1.3 | 2.7 ± 1.3 |
No significant difference between treatment groups. The FD score was the sum of the EPS score and the PDS score.